A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Fibroma
- Focus Adverse reactions
- Sponsors Endo Pharmaceuticals
Most Recent Events
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 19 Jan 2024 Planned End Date changed from 20 Feb 2026 to 1 May 2024.
- 19 Jan 2024 Planned primary completion date changed from 20 Feb 2026 to 1 May 2024.